391 completed. 391 Phase 2, 34 Phase 1, 28 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 391 | Completed 391 |
| Phase 1 | 34 | Completed 34 |
| Phase 3 | 28 | Completed 28 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder TQC3721 inhalation powder, Placebo for TQC3721 inhalation powder - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 195 | 2025-12-22 | 2026-06-18 |
| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 33 | 2025-10-06 | 2026-01-08 |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - COPD Acute Exacerbation | Phase 2 | Completed | Connect Biopharm LLC | 159 | 2025-08-12 | 2026-09-16 |
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 497 | 2025-07-31 | 2026-09-11 |
| Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD JKN2304 Inhalation Solution, Placebo, Formoterol Fumarate Inhalation Solution - COPD (Chronic Obstructive Pulmonary Disease), COPD | Phase 2 | Completed | Joincare Pharmaceutical Group Industry Co., Ltd | 42 | 2025-07-22 | 2026-03-04 |
| Sedation vs No Sedation in Mechanically Ventilated COPD Patients Midalozam - Chronic Obstructive Pulmonary Disease, Respiratory Failure | Phase 2 | Completed | Al-Azhar University | 100 | 2025-04-14 | 2026-06-02 |
| A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils Placebo, Tozorakimab - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 98 | 2025-04-12 | 2026-07-14 |
| Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD AERO-001, AERO-002, AERO-007 - COPD | Phase 1 / Phase 2 | Completed | AeroRx Therapeutics Inc. | 24 | 2025-01-15 | 2025-08-01 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 240 | 2024-09-14 | 2025-04-11 |
| A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg) - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 46 | 2024-08-16 | 2026-02-09 |
| A Phase 2 Trial of JKN24011 in COPD JKN24011, Placebo - COPD (Chronic Obstructive Pulmonary Disease) | Phase 2 | Completed | Joincare Pharmaceutical Group Industry Co., Ltd | 215 | 2024-08-01 | 2026-10-15 |
| Anti-Platelets in Chronic Obstructive Pulmonary Disease dual anti-platelet therapy, Placebo - COPD, Emphysema | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2024-03-27 | 2026-05-14 |
| Oral Supplementation During PR Participation in COPD Urolithin A (Mitopure), Placebo - Copd | Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 22 | 2024-03-11 | 2026-10-15 |
| Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease 611 300 mg Q2W, 611 450 mg Q2W, Matching placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 142 | 2023-12-08 | 2025-11-20 |
| RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Vapendavir, Placebo - COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection | Phase 2 | Completed | Altesa Biosciences, Inc. | 52 | 2023-11-20 | 2025-09-30 |
| A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD OnabotulinumtoxinA, Placebo - COPD | Phase 2 | Completed | RMW Testing | 40 | 2023-10-01 | 2024-07-17 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 75 | 2023-08-23 | 2025-04-17 |
| Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease L-menthol, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | Region Skane | 20 | 2023-05-24 | 2025-12-09 |
| Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD Bevespi, Bretzri - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | University of Miami | 25 | 2023-04-11 | 2026-09-08 |
| Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy REGEND001 cell therapy, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Regend Therapeutics | 58 | 2022-12-06 | 2026-09-28 |
Showing 20 of 391. Sign in to see all of them.
Emphysema (42) · Bronchitis, Chronic (30) · Asthma (21) · Lung Diseases (19) · Respiratory Aspiration (12) · Pulmonary Emphysema (11) · Respiration Disorders (11) · Dyspnea (10) · Lung Diseases, Obstructive (9) · Bronchiolitis Obliterans Syndrome (8) · alpha 1-Antitrypsin Deficiency (7) · Inflammation (6) · Motor Activity (6) · Bronchitis (5)
Chronic Disease (391) · Disease Attributes (391) · Pathological Conditions, Signs and Symptoms (391) · Pathologic Processes (388) · Respiratory Tract Diseases (386) · Lung Diseases, Obstructive (382) · Lung Diseases (372) · Bronchial Diseases (58) · Infections (34) · Bronchitis (33) · Immune System Diseases (32) · Respiratory Tract Infections (32) · Respiration Disorders (27) · Hypersensitivity (23) · Respiratory Hypersensitivity (23)
Tiotropium Bromide (33) · Formoterol Fumarate (27) · Salmeterol Xinafoate (14) · Glycopyrrolate (13) · indacaterol (11) · aclidinium bromide (8) · Albuterol (6) · Ipratropium (6) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (5) · Fluticasone (5) · GSK573719 (5) · Inhalation (5) · revefenacin (5) · Aspirin (4) · BID protein, human (4)
GlaxoSmithKline (43) · AstraZeneca (38) · Boehringer Ingelheim (31) · Chiesi Farmaceutici S.p.A. (18) · Novartis (13) · Pearl Therapeutics, Inc. (12) · Novartis Pharmaceuticals (10) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (9) · Pfizer (8) · Dey (6) · Aeris Therapeutics (5) · Sunovion Respiratory Development Inc. (5) · US Department of Veterans Affairs (5) · Mylan Inc. (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3)
United States (168) · Germany (89) · United Kingdom (74) · Netherlands (41) · Canada (40) · Poland (40) · Bulgaria (26) · Hungary (26) · Spain (25) · Australia (24) · Belgium (24) · Russia (24) · Argentina (22) · Denmark (22) · Sweden (21)
Dave Singh, MD (7) · Colin Reisner, M.D. (6) · Esther Garcia, MD (6) · Dave Singh (4) · Gerard Criner, MD (3) · Mark Gotfried, MD (3) · Piotr Kuna, Professor (3) · Adam Wanner, MD (2)
PMID 24432712, PMID 25287629, PMID 33124005, PMID 19179484, PMID 21184620, PMID 22374920, PMID 29202767, PMID 30116551, PMID 34887657, PMID 37192443, PMID 15319045, PMID 16796497, PMID 17296644, PMID 17715164, PMID 18202351, PMID 18245142, PMID 18655841, PMID 18684848, PMID 18972276, PMID 19017883, PMID 19135348, PMID 19436683, PMID 19583857, PMID 19750190, PMID 20007923, PMID 20299628, PMID 20416390, PMID 20463178, PMID 20541381, PMID 20565161, PMID 20970976, PMID 20978028, PMID 21227674, PMID 21311694, PMID 21397482, PMID 21473764, PMID 21514398, PMID 21524765, PMID 21543158, PMID 21689019, PMID 21893650, PMID 21903737, PMID 22021788, PMID 22056369, PMID 22158330, PMID 22197578, PMID 22206353, PMID 22235841, PMID 22280813, PMID 22292600
2015 (9), 2009 (6), 2017 (5), 2018 (5), 2014 (3), 2008 (1), 2016 (1), 2019 (1), 4UH3TR002450-02 (1), K23HL141651 (1), P50AT000437 (1), R01AT005436 (1), R01HL033269 (1), R01HL081489 (1), R01NR008938 (1)